



Proteomics International

LABORATORIES LTD

ASX/Media Release

17 July 2018

ASX code: PIQ

Proteomics International secures new contract with BiosanaPharma as company approaches cash flow positive

Medical technology company Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ), which has recently licensed its world-leading PromarkerD predictive diagnostic test for diabetic kidney disease into the USA, has secured a contract with Dutch/Australian company BiosanaPharma to conduct an analytical comparability study on a drug treatment for allergic asthma.

- **Proteomics International secures its largest analytical services contract to date with a value of US\$260,000**
- **Proteomics International to perform bioanalytical testing of biosimilar allergic asthma drug for BiosanaPharma**
- **Agreement comes as Proteomics International experiences bumper fourth quarter of revenues from its analytical testing services for biosimilars and clinical trials**
- **Proteomics International nears cash flow positive position from analytical services operations, with new revenue from PromarkerD licences also expected later in 2018**

The analytical testing contract with BiosanaPharma is worth US\$260,000, making it Proteomics International's largest biosimilars contract to date. The study will examine BiosanaPharma's good manufacturing practice (GMP) production run to establish product quality by comparison against existing reference products from around the world.

Proteomics International managing director Dr Richard Lipscombe said the contract comes at an exciting period for the company, with a bumper fourth quarter positioning Proteomics International to become cash flow positive. "Our analytical business is growing strongly, led by our biosimilars testing and new revenue from the partnership with Linear Clinical Research for pharmacokinetic testing for clinical trials [ASX: 15 Nov 2016]," he said. "We're now poised to support the development of new diagnostic tools entirely through revenue generated from analytical services."

BiosanaPharma's biosimilar drug for treatment of allergic asthma is destined for clinical trials in January 2019. This latest contract comes after Proteomics International completed successful stability studies on earlier batches of the drug which support its safety approval [ASX 14 July 2017].

BiosanaPharma's Chief Operating and Chief Scientific Officer Dr Jaap Wieling said it was fantastic to have two quality focused companies like Proteomics International and BiosanaPharma working alongside each other. "There are multiple stages of the drug development pipeline, with quality and precision being key to bringing our exciting new drug to market," he said.

The drug is a biosimilar monoclonal antibody, which are complex generic drugs that copy existing biological medicines coming off patent. Biosimilars are required to show robust chemical comparability to the original product at every stage of development, and require precise quality control testing.

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

The global biosimilars drug market is expected to reach US\$23.63 billion by 2023 from US\$5.95 billion in 2018 as biopharmaceutical companies seek to replicate a host of blockbuster drugs coming off patent.

In the last six weeks Proteomics International has also completed licensing deals for its lead diagnostic product PromarkerD – the world leading predictive test for diabetic kidney disease – in the USA and Mexico [ASX 21 June 2018]. First royalties from these licences are expected later in 2018, and will further grow the company's revenue streams.

ENDS

For further information please contact:

Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com

Susan Fitzpatrick-Napier
[Public Relations & Media Contact]
Digital Mantra Group
T: +61 2 8218 2144
E: team@dmgpr.com

About Proteomics International Laboratories (PILL) (www.proteomicsinternational.com)

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. It received the world's first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the-art facilities located on Perth's QEII Medical Campus. The Company's business model uses its proprietary technology platform across three integrated areas of diagnostics, drug discovery and analytical services.

About BiosanaPharma (www.biosanapharma.com)

BiosanaPharma is a Dutch/Australian privately owned early-stage biotechnology company, founded on an innovative process for the production of monoclonal antibodies (mAbs), by which cost of goods can be reduced by 90-95%. With this GMP (Good Manufacturing Practice) validated process, BiosanaPharma manufactures the products in its mAb biosimilars pipeline, that will be brought to the market in collaboration with international marketing and sales partners.

For more information on BiosanaPharma please contact:

Dr Nettie Buitelaar MBA, Chief Business Officer
T: +31 610 026 742, E: nettie.buitelaar@biosanapharma.com